Abstract:A machine learning‐derived LCDS using peripheral blood transcriptomics enables early detection of lung cancer with high accuracy. Lower LCDS correlates with enhanced antitumor immunity, while higher LCDS associates with protumorigenic pathway activation. LCDS shows potential as a noninvasive biomarker for lung cancer screening and prognosis. Lung cancer continues to be the leading cause of cancer‐related mortality worldwide. Early detection and a comprehensive understanding of tumor‐immune interactions are crucial for improving patient outcomes. This study aimed to develop a novel biomarker panel utilizing peripheral blood transcriptomics and machine learning algorithms for early lung cancer diagnosis, while simultaneously providing insights into tumor‐immune crosstalk mechanisms. Leveraging a training cohort (GSE135304), we employed multiple machine learning algorithms to formulate a Lung Cancer Diagnostic Score (LCDS) based on peripheral blood transcriptomic features. The LCDS model's performance was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC) in multiple validation cohorts (GSE42834, GSE157086, and an in‐house dataset). Peripheral blood samples were obtained from 20 lung cancer patients and 10 healthy control subjects, representing an in‐house cohort recruited at the Sixth People's Hospital of Chengdu. We employed advanced bioinformatics techniques to explore tumor‐immune interactions through comprehensive immune infiltration and pathway enrichment analyses. Initial screening identified 844 differentially expressed genes, which were subsequently refined to 87 genes using the Boruta feature selection algorithm. The random forest (RF) algorithm demonstrated the highest accuracy in constructing the LCDS model, yielding a mean AUC of 0.938. Lower LCDS values were significantly associated with elevated immune scores and increased CD4+ and CD8+ T‐cell infiltration, indicative of enhanced antitumor‐immune responses. Higher LCDS scores correlated with activation of hypoxia, peroxisome proliferator‐activated receptor (PPAR), and Toll‐like receptor (TLR) signaling pathways, as well as reduced DNA damage repair pathway scores. Our study presents a novel, machine learning‐derived peripheral blood transcriptomic biomarker panel with potential applications in early lung cancer diagnosis. The LCDS model not only demonstrates high accuracy in distinguishing lung cancer patients from healthy individuals but also offers valuable insights into tumor‐immune interactions and underlying cancer biology. This approach may facilitate early lung cancer detection and contribute to a deeper understanding of the molecular and cellular mechanisms underlying tumor‐immune crosstalk. Furthermore, our findings on the relationship between LCDS and immune infiltration patterns may have implications for future research on therapeutic strategies targeting the immune system in lung cancer.

P2.11-01 Blood Transcriptomics Enables Detection of Pre-Invasive and Minimally-Invasive Lung Adenocarcinoma

Novel Blood-Based, Five-Gene Biomarker Set For The Detection Of Colorectal Cancer

Use of Peripheral Blood Mrna Signatures to Distinguish Colorectal Cancer Patients from Colonoscopy-Negative Patients

A Peripheral Blood Transcriptomic Biomarker Panel Identified by Multiple Machine Learning Algorithms Enables Early Diagnosis and Prognosis Prediction in Lung Cancer

Using peripheral blood mRNA signature to distinguish between breast cancer and benign breast disease in non-conclusive mammography patients.

Peripheral blood mRNA signature for colorectal cancer screening.

Development of a novel blood-based RNA gene expression platform for early-stage lung cancer diagnosis.

P2.11-05 Peripheral Blood-Based T Cell Receptor Signatures As Potential Biomarkers for Early Diagnosis of Lung Cancer

Validation of a blood protein signature for non-small cell lung cancer

A Blood-Based Three-Gene Signature for the Non-Invasive Detection of Early Human Hepatocellular Carcinoma.

Identification of Biomarkers for the Detection of Early Stage Lung Adenocarcinoma by Microarray Profiling of Long Noncoding RNAs.

Blood-based DNA Methylation Panel for the Early Diagnosis of Lung Cancer

Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.

Data from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer

A Panel of Platelet Circrnas Serve As Biomarker for Lung Cancer Detection

The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

Genomic analyses based on pulmonary adenocarcinoma in situ reveal early lung cancer signature

Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes

Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study

A Blood-Based 22-Gene Expression Signature for Hepatocellular Carcinoma Identification

Machine learning‐derived peripheral blood transcriptomic biomarkers for early lung cancer diagnosis: Unveiling tumor‐immune interaction mechanisms